IMTherapeutics is a technology company.
IMTherapeutics has raised $10.0M across 1 funding round.
IMTherapeutics has raised $10.0M in total across 1 funding round.
No company named IMTherapeutics appears in current records as a technology company. The query likely refers to Perspective Therapeutics (formerly Im Therapeutics or similar naming evolution), a radiopharmaceutical firm developing image-guided, targeted alpha-particle therapies (TATs) for cancer treatment[1]. It builds Pb-212-based radiotherapies using proprietary targeting peptides conjugated to radioisotopes via a Pb-specific chelator, enabling tumor imaging with Pb-203 followed by alpha-particle delivery with Pb-212 for precise cancer cell destruction[1]. This serves oncology patients and physicians, solving limitations of conventional radiotherapy by delivering high-energy alpha radiation directly to tumors, minimizing healthy tissue damage, reducing resistance, and optimizing patient selection through theranostics[1].
The company targets solid tumors with its platform, emphasizing short-range alpha particles for potent killing efficacy[1]. Growth momentum includes advancing multiple programs leveraging the Pb-203/212 isotope pair, positioning it at the forefront of radiopharmaceutical innovation amid rising demand for targeted therapies[1].
Perspective Therapeutics emerged from advancements in radiopharmaceutical technology, focusing on Pb-212 alpha-particle therapies, though specific founding year, founders, or early traction details are not detailed in available sources[1]. The company's backstory centers on pioneering image-guided TATs, evolving from peptide-based targeting to integrate theranostics for pre-treatment tumor confirmation, marking a pivotal shift toward precision oncology[1].
This humanizes the effort as a response to unmet needs in cancer care, where traditional methods fall short, driving innovation in alpha-emitter delivery systems[1].
Perspective Therapeutics rides the radiopharmaceutical wave, particularly alpha-particle therapies, amid surging investment in precision oncology driven by successes like targeted radioligands[1]. Timing aligns with advances in isotope production and peptide engineering, fueled by market forces such as aging populations, rising cancer incidence, and demand for less invasive treatments over chemotherapy[1].
It influences the ecosystem by advancing TATs, potentially setting standards for theranostics and inspiring hybrid imaging-therapy platforms across biotech[1].
Pipeline expansion in Pb-212 programs signals robust momentum, with AI integration and partnerships likely accelerating clinical trials[1]. Trends like scalable isotope supply and combo therapies with immunotherapy will shape its path, evolving its role from innovator to potential market leader in alpha-emitters. Watch for Phase II/III data validating TAT superiority, tying back to its core mission of treating cancer from the inside out[1].
IMTherapeutics has raised $10.0M in total across 1 funding round.
IMTherapeutics's investors include T1D Fund.
IMTherapeutics has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in October 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2019 | $10.0M Series A | T1D Fund |